CJC-1295 and ipamorelin are almost always sold and prescribed together, and the human evidence for the pair is zero: no trial has ever given the two compounds together. The pair is usually sold as CJC peptide or cjc 1295, and the short name hides the distinction that matters most here — the DAC and no-DAC forms are different molecules. That is not unique to this pairing — a registry census of every named blend on the market returned the same answer for all of them. Each has a small human literature of its own, in forms and by routes that differ from what clinics dispense. This page reports the trial doses, the clinic doses, and the arithmetic the guides use, with their sources, and it says where the two sets of numbers fail to meet. It does not recommend anything. How brands appear on this site is set out on our disclosure page.
What they are
CJC-1295 is an analogue of growth-hormone-releasing hormone. It exists in two forms that share a name: CJC-1295 with DAC (drug affinity complex), which binds albumin and lasts about a week, and CJC-1295 without DAC, also called modified GRF 1-29, which lasts minutes. That week is the longest figure for any unapproved compound in this catalogue, as the chart of published half-lives sets out alongside the labelled drugs. The human trials are of the DAC form; the compounded blends are usually the no-DAC form. Ipamorelin is a growth hormone secretagogue, a pentapeptide that acts on the ghrelin receptor — as does the secretagogue Japanese hospitals use as a diagnostic test, whose dose record runs the other way, from clinical practice back into the market. Its human studies are intravenous pharmacology and a surgical trial. Both act upstream of insulin-like growth factor 1, which is where the engineered IGF-1 analogue sold as LR3 enters the same conversation from the other end — with a far thinner file. Both compounds appear under S2.2.4 of the 2026 WADA Prohibited List, prohibited at all times; FDA lists ipamorelin acetate in category 2 for 503B compounding, "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities" (FDA). What the with-DAC trials measured, and the body-composition outcomes they never reported, are set out in CJC-1295's human results.
The trial doses
| Study | Substance, route | Doses | Population and finding |
|---|---|---|---|
| Teichman et al., JCEM 2006 | CJC-1295 with DAC, subcutaneous | Ascending single doses; then two or three weekly or biweekly doses; "well tolerated, particularly at doses of 30 or 60 microg/kg" | Healthy adults aged 21–61, two randomized placebo-controlled trials of 28 and 49 days; GH up 2- to 10-fold for 6 days or more, IGF-I up 1.5- to 3-fold for 9–11 days after one injection; half-life 5.8–8.1 days; no serious adverse reactions |
| Gobburu et al., Pharm Res 1999 | Ipamorelin, intravenous infusion | 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes | 8 healthy men per level; a single GH pulse peaking at 40 minutes at every dose; half-life 2 hours |
| Beck et al., Int J Colorectal Dis 2014 | Ipamorelin, intravenous | 0.03 mg/kg twice daily, postoperative day 1 to 7 | 114 bowel-resection patients, randomized, placebo-controlled; time to first tolerated meal 25.3 vs 32.6 hours, not significant |
For scale: 30 to 60 mcg/kg of CJC-1295 with DAC is 2.25 to 4.5 mg for a 75 kg adult, given weekly or every two weeks. The clinic figure for the no-DAC form, 100 to 300 mcg nightly, is a tenth to a fortieth of that per injection, of a different molecule, on a different schedule. Ipamorelin's trial doses are intravenous and per kilogram (0.03 mg/kg is 2.25 mg for 75 kg, twice daily, in a hospital); the clinic figure is 100 to 300 mcg subcutaneously. Neither trial set is a dose-finding study for the use the clinics describe, and neither used the route.
Ipamorelin is also sold beside a different partner, the GHRH fragment sermorelin, and the two compounds' records could hardly be shaped less alike — the table on our ipamorelin vs sermorelin page sets them side by side, and what the adult sermorelin trials gave is several times the figure clinics now state.
The clinic and compounding doses
| Source | What it states | Kind of source | Date opened and link |
|---|---|---|---|
| Beverly Hills Rejuvenation Center | Starting dose "100 mcg of each peptide per dose, injected subcutaneously once daily at bedtime on an empty stomach, five days per week"; titration to "200–300 mcg of each per dose, sometimes split into two or three daily injections"; timing "≥2–3 hr after eating carbohydrates"; cycles "8–12 weeks" then a break with labs; CJC-1295 with DAC "1–2 mg once or twice weekly" | Clinic guide | Page dated 2026-07-24 |
| Clinic and vendor pages returned by a 2026-09-05 search (Perfect B, PS Peptides, Path to Peptides, Peptide Mind, Wittmer clinic) | 100–300 mcg of each per injection, most starting at 100 mcg once or twice daily; some describe 300–500 mcg of total blend two to three times daily | Clinic and vendor guides, as summarized; not individually opened | Range only |
The clinic guide's own framing is the honest one: the pages we opened describe the figures as convention and note there is no validated human dose for the combination.
Reconstitution arithmetic as the guides state it
The Beverly Hills guide gives two configurations. A blended vial containing 5 mg of each peptide, reconstituted with 2 mL of bacteriostatic water, is 2.5 mg/mL of each, or 25 mcg of each per U-100 unit: 100 mcg of each is 4 units, 200 mcg is 8, 300 mcg is 12. Two separate 2 mg vials, each with 1 mL, are 2 mg/mL, or 20 mcg per unit: 100 mcg is 5 units per peptide. Our reconstitution page has the procedure as an FDA label describes it and the arithmetic for any combination; our storage page covers solutions.
Timing, as the guides explain it
Bedtime, on an empty stomach, two to three hours after the last carbohydrate: the rationale the clinic page gives is that the largest natural GH pulse occurs in early slow-wave sleep and that food, particularly carbohydrate, suppresses GH release. That is a physiological argument, and a reasonable one; it has not been tested for this combination in a trial.
What is not known
Whether the no-DAC form of CJC-1295 with ipamorelin, at the clinic doses, changes body composition, strength or anything else in a human; the safety of the combination beyond the single-compound pharmacology studies; and what the immunogenicity risk FDA cites for compounded ipamorelin amounts to in practice. MuscleLedger's muscle-growth evidence ledger scores both compounds; nothing on this page is a recommendation.
Two further secretagogues in this catalogue return zero registered trials and are not therefore unstudied, which is the reading error this site has now made twice. GHRP-2's literature is Japanese and clinical; GHRP-6's is Cuban, and it includes the only full human pharmacokinetic study any compound in this class has — nine volunteers, three intravenous dose levels, a validated assay. Ipamorelin's own two-hour terminal figure above is one of only three in this catalogue measured in people.
A related compound reaches the growth-hormone axis from the opposite direction and has an even emptier file. AOD-9604 is a fragment of the hormone itself rather than something that provokes its release, and counting its published literature returns more papers on how anti-doping laboratories detect it than primary studies of what it does in humans — of which the indexed literature holds none. What the two 2006 trials recorded as side effects — headache in 63% against 14% on placebo, flushing in up to every high-dose injection — and the phase 2 trial that stopped after a death are set out on our CJC-1295 side effects page. The ipamorelin half of the pairing has a thinner harm record still, read report by report on what is known about ipamorelin's side effects.
Sources and dates
Opened 2026-09-05: Teichman et al. 2006 (PMID 16352683); Gobburu et al. 1999 (PMID 10496658); Beck et al. 2014 (PMID 25331030); Beverly Hills Rejuvenation Center guide (2026-07-24); FDA's category-2 bulk-substances page (updated 2026-04-22); the 2026 WADA Prohibited List. Corrections go to the contact page.